| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/04/2001 | CA2376023A1 Therapeutic agents |
| 01/04/2001 | CA2375972A1 Pharmaceutical composition containing sibutramine and orlistat |
| 01/04/2001 | CA2375952A1 Reverse-turn mimetics and methods relating thereto |
| 01/04/2001 | CA2370081A1 Lpl variant therapeutics |
| 01/04/2001 | CA2369839A1 Compositions of insulin and insulin-related peptide for treating diabetes |
| 01/04/2001 | CA2369308A1 Vla-4 inhibitor compounds |
| 01/04/2001 | CA2342361A1 Process for selective lactonization |
| 01/03/2001 | EP1065208A1 Substituted purine derivatives as inhibitors of cell adhesion |
| 01/03/2001 | EP1064965A2 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
| 01/03/2001 | EP1064964A2 Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications |
| 01/03/2001 | EP1064949A2 Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications |
| 01/03/2001 | EP1064943A1 Combination having antilipemic activity substantially free from toxic or side effects due to antilipemic drugs |
| 01/03/2001 | EP1064935A1 Solid thermoformable controlled-release pharmaceutical composition |
| 01/03/2001 | EP1064274A1 Benzenesulfonamide derivatives and their use as medicaments |
| 01/03/2001 | EP1064262A1 Substituted isoindolones and their use as cyclic gmp modulators in medicaments |
| 01/03/2001 | EP1064015A2 Receptor derived peptides as modulators of receptor activity |
| 01/03/2001 | EP1064000A1 Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders |
| 01/03/2001 | EP1063991A1 Statin-matrix metalloproteinase inhibitor combinations |
| 01/03/2001 | EP1063988A1 Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor ofmacrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| 01/03/2001 | EP1063980A2 Methods for decreasing beta amyloid protein production |
| 01/03/2001 | EP1063973A1 Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
| 01/03/2001 | EP1063971A1 Controlled release oral tablet having a unitary core |
| 01/03/2001 | EP0934060A4 Dietary supplements |
| 01/03/2001 | EP0902624B1 Composition and its use as a food supplement or for lowering lipids in serum |
| 01/03/2001 | EP0842169B1 Benzothiophene compounds |
| 01/03/2001 | EP0832057B1 Diaromatic propynyl or dienyl compounds |
| 01/03/2001 | CN1278812A 2-aryl-3-aroylbenzo [b] thiophenes for treatment of estrin deficiency |
| 01/03/2001 | CN1278811A 2-Arylbenzo[b] thiophenes useful for the treatment of estrogen deprivtion syndrome |
| 01/03/2001 | CN1278810A Substituted benzodihydropyran derivatives |
| 01/03/2001 | CN1278809A Substituted benzodihydropyran derivatives |
| 01/03/2001 | CN1278802A Benzoxazine and Benzothiazine derivatives and their use in pharmaceuticals |
| 01/03/2001 | CN1278800A Cyclohexane derivatives difunctionalised in 1.4 as ligands of 5T hia receptors |
| 01/03/2001 | CN1278794A Substituted di-hydroxyl-indol derivatives as protein tyrosine kinase and as protein serine/threenine kinase inhibitors |
| 01/03/2001 | CN1278785A Vanadium complexes of monohydroxamates and pharmaceutical compositions comprising them |
| 01/03/2001 | CN1278738A Release-sustaining agent for drugs and sustained-release pharmaceutical composition containing same |
| 01/03/2001 | CN1278736A Hmanized antibodies to human gp39, compositions containing and therapeutic use thereof |
| 01/03/2001 | CN1278725A Indeno [1,2-c]-naphtho [1,2-C]- and benzo [6,7] cyclohepta [1,2-C] pyrazole derivatives |
| 01/03/2001 | CN1278554A Antilipemic haw vinegar and its production process |
| 01/03/2001 | CN1060173C Heterocyclic compound with activity against diabetes and preparation nad application of same |
| 01/03/2001 | CN1060171C Substituted biphenyl isoxazole sulfonamides |
| 01/03/2001 | CN1060074C Chinese patent drug for treating diabetes and gout |
| 01/02/2001 | US6169105 Potentiating the action of paroxetine in increasing the availability of serotonin, norepinephrine and dopamine in the brain by administering paroxetine to a patient in need thereof in combination with way 100635 |
| 01/02/2001 | US6169100 Pharmaceutical composition |
| 01/02/2001 | US6169099 Pharmaceutical composition |
| 01/02/2001 | US6169090 Heterocyclic compounds and their therapeutic use |
| 01/02/2001 | US6169087 An enzyme inhibitor for treating type i diabetes, type ii diabetes, impaired glucose tolerance, insulin resistance, obesity, autoimmune diseases, diseases with dysfunctions of the coagulation system, allergic diseases, cancer, psoriasis |
| 01/02/2001 | US6169070 Mer receptor activation by gas6 |
| 01/02/2001 | US6168933 Nucleotide sequences coding a transport protein; for the classification, diagnosis, prevention, and treatment of defects in cell proliferation, lipid metabolism and transport |
| 01/02/2001 | US6168792 Materials and methods for detection and treatment of immune system dysfunctions |
| 01/02/2001 | CA2187274C Treatment of partial growth hormone insensitivity syndrome |
| 01/02/2001 | CA2184696C Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives |
| 01/02/2001 | CA2184693C Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide derivatives |
| 01/02/2001 | CA2184692C Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide disulfide derivatives |
| 01/02/2001 | CA2174034C Novel tricyclic amides, processes for their preparation and the pharmaceutical compositions which contain them |
| 01/02/2001 | CA2094424C Method of treating osteoporosis with 1.alpha.,24(r)-dihydroxy-22(e)-dehydro-vitamin d3 |
| 01/02/2001 | CA2064039C Treatment to reduce edema for brain and musculature injuries |
| 12/30/2000 | CA2313131A1 Compositions and treatment for diabetic complications |
| 12/30/2000 | CA2313105A1 Treatment for diabetic complications |
| 12/30/2000 | CA2313063A1 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
| 12/30/2000 | CA2313011A1 Encapsulation of active ingredients |
| 12/28/2000 | WO2000079003A1 Polymorphisms in the human hmg-coa reductase gene |
| 12/28/2000 | WO2000078980A1 Method for producing plants with increased flavonoid and phenolic compound content |
| 12/28/2000 | WO2000078972A2 Regulation with binding cassette transporter protein abc1 |
| 12/28/2000 | WO2000078971A2 Atp binding cassette transporter protein abc1 popypeptides |
| 12/28/2000 | WO2000078970A1 Nucleic and proteinic acids corresponding to human gene abc1 |
| 12/28/2000 | WO2000078953A2 Human transport proteins |
| 12/28/2000 | WO2000078952A2 Human rna metabolism proteins (rmep) |
| 12/28/2000 | WO2000078950A2 Differentially expressed genes in the adipocytes of obese mice |
| 12/28/2000 | WO2000078941A2 Methods and products for manipulating uncoupling protein expression |
| 12/28/2000 | WO2000078940A1 In vivo insect model system for type-2 diabetes |
| 12/28/2000 | WO2000078805A1 Peptide having preptin functionality |
| 12/28/2000 | WO2000078804A1 Immune response regulatory proteins |
| 12/28/2000 | WO2000078794A1 Cysteinyl protease inhibitors |
| 12/28/2000 | WO2000078789A1 Aromatic and heterocyclic derivatives of phytosterols and/or phytostanols for use in treating or preventing cardiovascular disease |
| 12/28/2000 | WO2000078753A1 Process for the preparation of paroxetine and structurally related compounds |
| 12/28/2000 | WO2000078751A2 Compounds for use in treatment of neurological disorders |
| 12/28/2000 | WO2000078744A1 Thiochroman derivatives against neurological disorders |
| 12/28/2000 | WO2000078736A1 1,4-diazacycloheptane derivatives as neuroprotective agents |
| 12/28/2000 | WO2000078726A1 Imidazoline derivatives for the treatment of diabetes, especially type ii diabetes |
| 12/28/2000 | WO2000078697A2 High molecular weight primary aliphatic alcohols obtained from beeswax and pharmaceutical use thereof |
| 12/28/2000 | WO2000078360A1 Compositions and methods for the treatment or prevention of autoimmune disorders |
| 12/28/2000 | WO2000078320A1 Cartilage enhancing food supplements and methods of preparing the same |
| 12/28/2000 | WO2000078319A1 Dihydropyrazine derivatives as npy antagonists |
| 12/28/2000 | WO2000078313A1 Arylthiazolidinedione and aryloxazolidinedione derivatives |
| 12/28/2000 | WO2000078312A1 Arylthiazolidinedione and aryloxazolidinedione derivatives |
| 12/28/2000 | WO2000078266A2 Interferon tau mutants and methods for making them |
| 12/28/2000 | WO2000078145A1 Macrophage scavenger receptor antagonists |
| 12/28/2000 | WO2000078143A1 Method of increasing the content of flavonoids and phenolic substances in plants |
| 12/28/2000 | WO2000061551A3 Pyrimidine-2-one derivatives as integrin receptor ligands |
| 12/28/2000 | WO2000043495A3 33 human secreted proteins |
| 12/28/2000 | WO2000043373A3 Kinase inhibitors |
| 12/28/2000 | WO2000043034A3 Monodisperse hexameric acylated insulin analog formulations |
| 12/28/2000 | WO2000034474A3 Growth factor homolog zvegf3 |
| 12/28/2000 | WO1999052493A3 Compounds that inhibit the binding of integrins to their receptors |
| 12/28/2000 | DE19929065A1 Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and HMG-CoA reductase inhibitor |
| 12/28/2000 | DE19917705C1 Mittel zur Therapie von Hyperphosphatämie Means for therapy of hyperphosphatemia |
| 12/28/2000 | CA2382425A1 Interferon tau mutants and methods for making them |
| 12/28/2000 | CA2377698A1 Dihydropyrazine derivatives as npy antagonists |
| 12/28/2000 | CA2377530A1 Compositions and methods for the treatment or prevention of autoimmune disorders |
| 12/28/2000 | CA2377288A1 Macrophage scavenger receptor antagonists |